Effect of high-dose plerixafor on CD34+ cells mobilization in healthy stem-cell donors: results of a randomized crossover trial


Disclosures: Gary Calandra worked for Sanofi but was not involved in the supply of study drug. The other authors have no conflict of interest to declare.